Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > The best thing that could happen is that---
View:
Post by Impalaman on Jun 05, 2022 8:50am

The best thing that could happen is that---

Our stock price gets us into the 2.00 plus range after the 4th Q--results ---BTD---then in early 2023---we apply for a nazdqx listing----that will fill the cofers----and get some attention.
Comment by LaserStock29 on Jun 06, 2022 9:48am
We left 2019 atm with the same idea... It's the right price to do a raise at.. and tbh might not even need to Licensing out ACT $$$ Licensing out Tld 1433 or Ruthenium for other indications $$$ UP FRONT CASH PAYMENTS Would be a real shame If shareholders got hoodwinked into a predatory financing again. Need to see the stock price hit .50 by the agm
Comment by skys1 on Jun 06, 2022 10:00am
Just how many times does management have to tell you they have enough cash through the Ph 2 process, before you will believe them???
Comment by Rumpl3StiltSkin on Jun 06, 2022 10:05am
Exactly Skys, And they demonstated this in the last qtrly update. Which showed the till had over $2.5M and didn't even include any last minute May exercised warrants...
Comment by LaserStock29 on Jun 06, 2022 10:16am
I'd like to see a PowerPoint like we got after the 17m oversubscribed that broke down trial costs etc. It's not enough to simply say trust us How did 14.5m get allocated? I want a breakdown of the expenses. Surely management tracked each transaction from that 17m put it in a pie chart. Or something. Not hard at all. In any case. The more this price drops.. the forks for beef potatoes turn ...more  
Comment by Legit62 on Jun 06, 2022 10:44am
Totally agree Skys1, lets let this roll out and once we get BTD and AA, Sp will take care of itself and we wont have to deal with 150 shares dropping us almost 6%, It would be nice though to get some good news and updated results at this next meeting, maybe to quiet the nonsense down
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250